Tenax Therapeutics, Inc. (TENX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tenax Therapeutics, Inc. on September 9, 2025, covering events occurring on September 3, 2025. The Company is a Delaware corporation focused on the development and commercialization of pharmaceutical products, specifically those containing levosimendan.
Key Financial Metrics
This filing is a Current Report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Agreements
On September 3, 2025, Tenax Therapeutics, Inc. entered into an Amendment to its License Agreement with Orion Corporation. Key terms include:
- Expanded Rights: The Company now holds exclusive worldwide rights to develop, commercialize, manufacture, and have manufactured any orally-administered pharmaceutical product containing levosimendan.
- Manufacturing Rights: Rights were expanded to include the manufacturing of subcutaneously administered products containing levosimendan, in addition to existing development and commercialization rights.
- Supply Agreement: Orion Corporation agreed to supply levosimendan as reasonably necessary for the development of orally-administered products.
- Pricing: The price for levosimendan is set in the low triple-digit thousands of Euros per kilogram.
Outlook, Risks, and Management Commentary
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a discussion of risks beyond the standard incorporation of the full agreement terms. The summary of terms is subject to the complete text of the Amendment attached as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the specific pricing tiers and volume commitments within the full text of the Amendment (Exhibit 10.1), as only a price range is disclosed in the summary.
- Confirm the impact of the expanded manufacturing rights on the Company's operational capacity and capital requirements.
- Review the supply chain dependencies created by the agreement with Orion Corporation for levosimendan.
- Check for any redacted portions in Exhibit 10.1 that may contain material financial obligations or termination clauses.